Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 131Lymphoma 117Lymphoma, Large B-Cell, Diffuse 80Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Multiple Myeloma 50Lymphoma, Non-Hodgkin 46Lymphoma, Follicular 45Leukemia 39Hodgkin Disease 33Lymphoma, Mantle-Cell 32Burkitt Lymphoma 32Lymphoma, Large-Cell, Immunoblastic 21Lymphoma, Large-Cell, Anaplastic 20Lymphoma, B-Cell, Marginal Zone 19Neoplasm Metastasis 16Leukemia, Lymphocytic, Chronic, B-Cell 16Neoplasms, Plasma Cell 15Neoplasms 13Lymphoma, T-Cell, Peripheral 10Dendritic Cell Sarcoma, Interdigitating 10Recurrence 9Lymphoma, B-Cell 9Primary Myelofibrosis 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Immunoblastic Lymphadenopathy 8Blast Crisis 7Lymphoma, T-Cell 6Graft vs Host Disease 6Waldenstrom Macroglobulinemia 5Prostate Cancer Metastatic 5

Interventions

masitinib 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Castrate Resistant Prostate Cancer × Prednisone × Clear all
NCT03761225 2023-09-29

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

AB Science

Phase 3 Completed
714 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡